Naismith et al. state that they preferentially recruited patients with severe optic neuritis (with ≤20/200 vision) and poor recovery (to <20/40 vision).This bias in selecting study participants ...
OCS-05 demonstrates safety and efficacy in treating acute optic neuritis, receiving FDA IND clearance for clinical development in the U.S. Small sample size of only 36 patients in the Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback